Hi [[ session.user.profile.firstName ]]

How to Improve Forensic Science

The current institutional structure of police forensics gives each lab a monopoly in the analysis of the police evidence it receives.
Forensic scientists have inadequate incentives to produce reliable analyses of police evidence. We should have "competitive self regulation" for pol
The current institutional structure of police forensics gives each lab a monopoly in the analysis of the police evidence it receives.
Forensic scientists have inadequate incentives to produce reliable analyses of police evidence. We should have "competitive self regulation" for police forensics. Each jurisdiction would have several competing forensic labs. Sometimes, evidence would be divided and sent to three separate labs. Chance would determine which labs would receive evidence to analyze. Competitive self regulation improves forensics by creating incentives for error prevention, detection and correction. Surprisingly, it would also reduce the costs of running the criminal justice system.
Recorded Dec 4 2008 49 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Roger Koppl, Director of the Institute for Forensic Science Administration
Presentation preview: How to Improve Forensic Science
Recommended for you:
  • Date
  • Rating
  • Views
  • What does 'the cloud' mean for pharma? What does 'the cloud' mean for pharma? Athula Herath (Novartis), Umang Patel (Babylon Health), Peter Emberson (UK Pharma IT Forum), Paul Tunnah (pharmaphorum) Recorded: May 4 2016 65 mins
    A unique Q&A session/open forum panel debate.

    It is likely that you interact with ‘the cloud’ on various devices, multiple times throughout the day. However, for pharma we have only just scratched the surface regarding what the cloud can offer in terms of security, connectivity and efficacy. ‘Business analytics’ and ‘cloud’ are often misunderstood.

    To answer this, pharmaphorum, in conjunction with industry stalwarts Equinix, present a unique Q&A event, offering the opportunity to ask any questions you may have around what the cloud can do, and how to remain compliant in utilising this technology.

    This debate is an open forum and the expert panel will offer insight about interaction between the cloud and pharma with a particular focus on:
    • Patient outcomes – The cloud and patients, what are the routes to improving outcomes?
    • Internet of things – As the ways to gather data and interact increase exponentially, how does the cloud support this? What are the opportunities and can we eliminate the risk?
    • Data and security – How to achieve compliance almost automatically.
    • Collaboration – Why and how the cloud enables true partnership working.
  • Disrupting and improving customer engagement with predictive insights Disrupting and improving customer engagement with predictive insights David Davidovic, Jerome Mead, Leilani Latimer, Paul Tunnah Recorded: Apr 27 2016 63 mins
    There are clear benefits for both Life Sciences companies and their customers in significantly improving the way they engage. Be it in terms of reputation, efficiency, profitability, or even relationship quality and longevity, engagement has and will always be the key to successful business practice.

    Recent exclusive research conducted in conjunction with Zephyr Health revealed that both frontline sales forces and sales management professionals want to improve engagement strategies with new technology utilizing predictive insights. However, despite having new tools available to them, sales teams remain heavily reliant on the same techniques that were being used decades ago.

    So what is the answer – how do life sciences companies disrupt this pattern and make significant strides to improve engagement?

    Working with Zephyr Health, we present an expert webinar that will answer this very question, bringing together industry experts to discuss why the disruption is critical, how it can be achieved, and the core role that predictive insights play in this process.

    As with all of our webcasts, this is an interactive debate designed to enable you to get the answers you need.

    Topics covered include:

    •Customer engagement challenges and trends: the need for disruptive customer engagement – what the survey revealed
    •The challenges facing Life Sciences customer engagement
    •Why technology is only partially solving the problem
    •The evolution of CRM: from historic analytics to current analytics to future analytics – knowing what your customer wants before they do
    •Overcoming internal blockers to change within Life Sciences – the roadmap for success
  • e-Medical excellence at launch e-Medical excellence at launch Fonny Schenck (CEO, Across Health) and Ben Harbour (MD, Across Health UK) Recorded: Apr 26 2016 60 mins
    This webinar will provide you with an overview how digital can be integrated into medical plans and what it takes to deliver multichannel medical excellence at launch.

    Key topics include:
    •Overview of typical launch categories and their key communication drivers and multichannel opportunities
    •The 4 main pre-launch stakeholders and how to integrate digital initiatives in a balanced medical mix whilst respecting legal and regulatory guidelines
    oeKOLs: Gathering insight and engagement planning
    oeHCPs: Channel selection to ensure immersive learning and education
    oePatients: Gathering treatment insight and prepare education & value-focused “beyond the-pill” strategies for launch
    oePayers: Establish value
    •Assess the clinical impact of e-medical programmes and how to create KPIs and dashboards to assess the success of your cross-channel activities
    •Prepare your organization for emedical excellence through multichannel skills development and enablement for MSLs and internal staff
  • The Creative Debate: Why creativity is key to true patient centricity in pharma The Creative Debate: Why creativity is key to true patient centricity in pharma Kai Gait, Maneesh Juneja, Lions Health jury member, Paul Tunnah Recorded: Apr 26 2016 66 mins
    Meeting the needs of both patients, and healthcare professionals, in today's fast changing communications landscape can be challenging, particularly against the backdrop of compliance. Putting creativity at the heart of the process can be the most effective way of tackling these challenges.

    Although the return on investment of creativity is not always easy to measure, the value it can bring to pharma and healthcare is increasingly evident.

    This webinar brings together a wealth of expertise to deliver case-study based evidence, interactive debate and practical advice on deriving competitive advantage from the creative process and ensuring patients are truly at the heart of your business.
  • Optimize Your Germ-Zapping Robot: Best practices & review of published studies Optimize Your Germ-Zapping Robot: Best practices & review of published studies Founder Dr. Mark Stibich, PhD Recorded: Apr 21 2016 60 mins
    PASSWORD: LightStrike -- Join this webinar to become an instant expert in xenon light room disinfection. Hear the latest evidence-based best practices for optimizing the use of Xenex Germ-Zapping Robots to tackle C. diff, MRSA and other difficult pathogens that linger in hospitals and post-acute care units.

    Hospitals across the country continue to publish infection rate reductions achieved using pulsed xenon light disinfection technology. Dr. Mark Stibich, Xenex Founder and Chief Scientific Officer, will discuss the published outcome studies to date and share best practices to help you reduce the risk of infection in your facility.
  • Optimize Your Germ-Zapping Robot: Best practices & review of published studies Optimize Your Germ-Zapping Robot: Best practices & review of published studies Founder Dr. Mark Stibich, PhD Recorded: Apr 20 2016 63 mins
    PASSWORD: LightStrike -- Join this webinar to become an instant expert in xenon light room disinfection. Hear the latest evidence-based best practices for optimizing the use of Xenex Germ-Zapping Robots to tackle C. diff, MRSA and other difficult pathogens that linger in hospitals and post-acute care units.

    Hospitals across the country continue to publish infection rate reductions achieved using pulsed xenon light disinfection technology. Dr. Mark Stibich, Xenex Founder and Chief Scientific Officer, will discuss the published outcome studies to date and share best practices to help you reduce the risk of infection in your facility.
  • LEAN High-Volume Hematology Solutions LEAN High-Volume Hematology Solutions Alan Neal, CSci, MSc, FIBMS, quality manager and lead of specialty, hematology, at Pathology Associates Recorded: Apr 19 2016 65 mins
    Learn how Beckman Coulter’s hematology and laboratory automation technologies have helped standardize procedures, deliver consistent turnaround time, reduce manual intervention, and achieve high auto validation rates. Alan Neal will share how his laboratory implemented Beckman Coulter automation and LEAN manufacturing principles.
  • The truth about delivering clinical research in the UK? The truth about delivering clinical research in the UK? Dr Matt Cooper, Business Development and Marketing Director Recorded: Mar 2 2016 34 mins
    •Are you looking to deliver your research within Europe?
    •Do you need multiple, reliable sites and experienced investigators?
    •Do you want to know why you should come to the UK?

    In the past the UK’s reputation for delivering clinical research was questionable. But that has all changed with the Department of Health’s investment in the clinical research network infrastructure in the UK.

    Over the last seven years the research landscape in the UK has improved dramatically allowing the UK to make great strides in delivering research for the Life Sciences industry. So whether you are a Pharmaceutical Company, Contract Research Organisation, Biotech, Med Tech or Diagnostic company we can help.

    The NIHR Clinical Research Network is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research. This session will be hosted by Dr Matt Cooper, Business Development and Marketing Director, of the National Institute for Health Research Clinical Research Network (NIHR CRN). It will include performance data that will demonstrate why the UK should be your first choice for running clinical research studies.

    You can discover:
    •How much the UK’s market volume of commercial contract research has grown and how we recruited over 34,000 patients to commercial clinical trials in 2014/15
    •What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR CRN)
    •The free feasibility service run by the NIHR CRN
    •How to gain access to our experienced clinical experts
    •How we are keeping clinical research in the public eye
    •How the UK is sharpening its competitive edge by achieving more key first global patients

    The NIHR CRN is exhibiting at the BioPharma Asia Convention 2016, visit stand B22 from 22-24 March to find out more about what we do to support clinical research and how we can help you deliver your studies in the UK.
  • Designing the Next Phase in Genome Editing: Advanced CRISPR Applications Designing the Next Phase in Genome Editing: Advanced CRISPR Applications Jeremy Lehmann- CRISPR Product Specialist, Functional Genomics, MilliporeSigma Recorded: Mar 1 2016 44 mins
    CRISPR Cas9 nucleases have revolutionized the field of genome editing enabling unprecedented efficiency of gene targeting in a vast array of cell types and organisms. Even with such powerful technology at hand, researchers who are new to the field may find genome modification to be challenging and time-consuming. As CRISPR becomes a focus of the molecular biology research community, MilliporeSigma seeks to share the best approaches learned and methods applied in our years of genome editing experience. Today’s presentation will focus on practical applications of CRISPR for pristine genome editing to achieve knockout as well as specific sequence changes to include donor-mediated snps, reporter-tags and conditional knockouts. Special attention will be paid to design considerations for the donor constructs necessary to achieve specific sequence changes. Finally, the frontiers of CRISPR technology, including synthetic crRNA to fast-track genome editing experiments, whole genome screening and targeted gene activation will be explored.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: How to Improve Forensic Science
  • Live at: Dec 4 2008 7:15 pm
  • Presented by: Roger Koppl, Director of the Institute for Forensic Science Administration
  • From:
Your email has been sent.
or close
You must be logged in to email this